World Health Organization Raises Alert Over Acute Scarcity of Weight-Loss Jabs
Fewer than a tenth of individuals eligible to benefit from obesity jabs such as Wegovy have access to them, caution the WHO as it issues its first recommendations on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for more widespread and fairer availability to this class of drugs.
According to estimates, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.
"The latest guidelines acknowledges that obesity is a lifelong illness that can be addressed with comprehensive and lifelong support," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are significant barriers to widespread access to the jabs that can assist patients in reducing considerable weight, explains the agency.
Skinny Jab Scarcity
Despite the present most favorable scenario, the manufacturing of such drugs would only suffice for around 100 million people – under 10% of those who need them, per the WHO.
The advice urges governments and firms to widen availability, via approaches like voluntary licensing.
Exclusive production rights on semaglutide – the main ingredient of Novo Nordisk's Wegovy – is set to lapse in several countries in 2026.
How Weight-Loss Jabs Function
These medications replicate a natural hormone to slow digestion, curb appetite and boost satiety so users consume fewer calories.
Individuals usually see weight reduction within a few weeks of beginning the once-weekly jabs.
Evidence indicates people may regain a significant portion after a year of halting the medication, as their usual food cravings resume.
Being carrying excess weight elevates your chance for experiencing health problems, like type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight impacts people in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.
